Homology Medicines

Lexington, United States Founded: 2015 • Age: 11 yrs Acquired By Oxford BioMedica
Developer of gene therapies for rare genetic diseases
Request Access

About Homology Medicines

Homology Medicines is a company based in Lexington (United States) founded in 2015 was acquired by Oxford BioMedica in January 2022.. Homology Medicines has raised $127 million across 3 funding rounds from investors including Fidelity Investments, Pfizer and OXB. The company has 221 employees as of December 31, 2022. Homology Medicines operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.

  • Headquarter Lexington, United States
  • Employees 221 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $1.16 M
    -64
    as on Dec 31, 2023
  • Net Profit
    $-112.96 M
    -2157
    as on Dec 31, 2023
  • EBITDA
    $-101.43 M
    24
    as on Dec 31, 2023
  • Total Equity Funding
    $127 M (USD)

    in 3 rounds

  • Latest Funding Round
    $60 M (USD), Post-IPO

    Nov 09, 2020

  • Investors
  • Employee Count
    221

    as on Dec 31, 2022

  • Acquired by
    Oxford BioMedica

    (Jan 28, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Homology Medicines
Headcount 200-500
Employee Profiles 34
Board Members and Advisors 6
Employee Profiles
People
Deborah Kinch
Chief Development Officer
People
Brad Smith
Chief Financial & Business Officer
People
Paul Alloway
Chief Legal Officer
People
Melissa Gelormini
Vice President, Human Resources

Unlock access to complete

Board Members and Advisors
people
Arthur Tzianabos
Chairman

Unlock access to complete

Funding Insights of Homology Medicines

Homology Medicines has successfully raised a total of $127M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $60 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Post-IPO — $60.0M
  • First Round

    (16 Feb 2017)

  • Investors Count 13
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2020 Amount Post-IPO - Homology Medicines Valuation

investors

Aug, 2017 Amount Series B - Homology Medicines Valuation Deerfield
Feb, 2017 Amount Series A - Homology Medicines Valuation 5AM Ventures , Arch Venture Partners
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Homology Medicines

Homology Medicines has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Pfizer and OXB. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made in innovative life science companies globally.
Founded Year Domain Location
Early-stage and late-stage biotech and finance companies are funded.
Founded Year Domain Location
Venture capital and private equity firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Homology Medicines

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Homology Medicines

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Homology Medicines Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Homology Medicines

Homology Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
RNA interference-based therapeutics are developed for multiple disorders.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Homology Medicines

Frequently Asked Questions about Homology Medicines

When was Homology Medicines founded?

Homology Medicines was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Homology Medicines located?

Homology Medicines is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Is Homology Medicines a funded company?

Homology Medicines is a funded company, having raised a total of $127M across 3 funding rounds to date. The company's 1st funding round was a Series A of $43.5M, raised on Feb 16, 2017.

How many employees does Homology Medicines have?

As of Dec 31, 2022, the latest employee count at Homology Medicines is 221.

What is the annual revenue of Homology Medicines?

Annual revenue of Homology Medicines is $1.16M as on Dec 31, 2023.

What does Homology Medicines do?

Homology Medicines was established in 2015 in Lexington, United States, within the biotechnology sector. Gene therapies targeting rare genetic diseases are developed through a proprietary platform. This platform relies on gene editing and adeno-associated virus vectors sourced from natural human variants. Homologous recombination, a naturally occurring biological process, is harnessed to enable precise genetic modifications. Operations focus on advancing these therapies for clinical applications.

Who are the top competitors of Homology Medicines?

Homology Medicines's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Who are Homology Medicines's investors?

Homology Medicines has 14 investors. Key investors include Fidelity Investments, Pfizer, OXB, Temasek, and Arch Venture Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available